Experience of using the combined preparation insulin glargine + lixisenate in a patient with type 2 diabetes mellitus


DOI: https://dx.doi.org/10.18565/therapy.2020.8.142-148

Demidova T.Yu., Kishkovich Yu.S., Lobanova K.G.

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
Achieving glycemic targets is now a paramount concern in the treatment of patients with type 2 diabetes. On the way to achieving the goal, it is important to determine the target indicator of glycated hemoglobin (HbA1c) individually for each patient, based on his age, the presence of atherosclerotic cardiovascular diseases, the risk of severe hypoglycemia. The next step is to determine the laboratory indicator of HbA1c in this patient, to assess the difference from the target. Based on two indicators, the treatment tactics are determined, a rational combination of antihyperglycemic drugs is selected, taking into account the patient’s concomitant diseases. A large number of uncompensated patients or patients with newly diagnosed type 2 diabetes mellitus have HbA1c significantly above its target level. This article demonstrates a similar clinical case and describes the treatment tactics.
Keywords: combined hypoglycemic drug, prandial glycemia, fasting glycemia, lixisenatide, glucose toxicity, insulin glargine
Read entire article

Literature


  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск (дополненный). М., 2019. [Standards of specialized diabetes care. Ed. by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition (revised). M. 2019 (In Russ.)]. doi: 10.14341/DM221S1.

  2. IDF Diabetes Atlas. 9th Edition. 2019. URL: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf (date of access – 01.11.2020).

  3. Dedov I.I., Shestakova M.V., Benedetti M.M. et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016; 115: 90–95. doi: 10.1016/j.diabres.2016.02.010.

  4. Ahren B., Gautier J.F., Berria R. et al. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014; 16(9): 861–68. doi: 10.1111/dom.12290.

  5. Зырянов С.К., Дьяков И.Н. Клинико-экономический анализ фиксированной комбинации инсулина гларгин 100 ЕД/мл и ликсисенатида при интенсификации фармакотерапии сахарного диабета 2 типа. Качественная клиническая практика. 2018; 3: 4–13. [Ziryanov S.K., Dyakov I.N. Health technology assessement of the fixed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensification of diabetes mellitus type 2. Kachestvennaya klinicheskaya praktika. 2018; 3: 4–13 (In Russ.)]. doi: 10.24411/2588-0519-2018-10047.

  6. Инструкция по медицинскому применению препарата Соликва СолоСтар®. ЛП-004874. http://grls.rosminzdrav.ru/ (дата обращения – 01.11.2020). [Instructions for the medical use of Soliqua SoloStar®. ЛП-004874. http://grls.rosminzdrav.ru/ (date of access – 01.11.2020) (In Russ.)].

  7. Rosenstock J., Aronson R., Grunberger G. et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial. Diabetes Care. 2016; 39(11): 2026–35. doi: 10.2337/dc16-0917.

  8. Aroda V.R., Rosenstock J., Wysham C. et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. Diabetes Care. 2016; 39(11): 1972–80. doi: 10.2337/dc16-1495.

  9. Blonde L., Rosenstock J., Del Prato S. et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: The LixiLan-G randomized clinical trial. Diabetes Care. 2019; 42(11): 2108–16. doi: 10.2337/dc19-1357.


About the Autors

Tatyana Yu. Demidova, MD, professor, head of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 109263, Moscow, 4/1 Shkuleva Str. E-mail: t.y.demidova@gmail.com. ORCID: 0000-0001-6385-540X
Yulia S. Kishkovich, assistant of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, 1 Ostrovityaninova Str. E-mail: maximovajuly22@gmail.com
Kristina G. Lobanova, assistant of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, 1 Ostrovityaninova Str.


Similar Articles

Back to Content

Бионика Медиа